百时美施贵宝

US · BMY #158 按市值排名上市于 1970

59.75 -0.82 -1.35%

实时 - 追踪5344个代码 - 心跳于2秒前 · 2026-10-16 20:02

✦ 量化股权信号计算方式说明

减持

最近一期（2026/Q3）披露持股的机构数量减少了7家。
机构持股总比例下降了0.2个百分点。

机构持股

机构持股比例: 83.16% -0.22pp
机构数量: 2,897 -7
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund68.63%

Public Company3.88%

Hedge Fund2.87%

Government Pension Fund2.63%

Private Company2.13%

Sovereign Wealth Fund1.90%

Insurance Company0.35%

Family Office/Trust0.30%

VC/PE Fund0.17%

Corporate Pension Plan0.15%

Other17.15%

主要股东截至 2026-06-30

BlackRock 8.83% · 180.38M 股

Vanguard Capital Management, LLC 7.09% · 144.81M 股

State Street Global Advisors 5.01% · 102.41M 股

Charles Schwab Investment Management 3.31% · 67.60M 股

J.P. Morgan Asset Management, Inc. 2.89% · 59.10M 股

Other 72.86%

Geode Capital Management, LLC 2.76% · 56.44M 股

Vanguard Portfolio Management, LLC 2.29% · 46.87M 股

Norges Bank Investment Management 1.80% · 36.87M 股

T. Rowe Price Group, Inc. 1.55% · 31.73M 股

UBS Asset Management 1.55% · 31.72M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 36次买入 · 14次卖出

姓名	职务	持股比例
Sandra Leung	Executive Vice President	0.02%
David Elkins	Chief Financial Officer	0.01%
Christopher Boerner	Chief Operating Officer	0.01%
Theodore Samuels	Lead Independent Director	0.00%
Julia Haller	Independent Director	0.00%
Samit Hirawat	Executive VP & Chief Medical Officer of Drug Development	0.00%
Greg Meyers	Executive VP and Chief Digital & Technology Officer	0.00%
Adam Lenkowsky	Executive VP, Chief Commercialization Officer & Head of U.S. Oncology	0.00%
Karin Shanahan	Executive Vice President of Global Product Development & Supply	0.00%
Robert Plenge	Executive VP, Chief Research Officer & Head of Research	0.00%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-10-01	Cari Gallman	Executive Vice President of Corporate Affairs	Derivative Exercise and Sale	-2,332	$61.15
2026-10-01	Cari Gallman	Executive Vice President of Corporate Affairs	Derivative Exercise and Retained	+2,227	--
2026-09-29	Derica Rice	Independent Director	Other Derivative Acquisition	+620	--
2026-09-29	Phyllis Yale	Independent Director	Other Derivative Acquisition	+560	--
2026-09-29	Peter Arduini	Independent Director	Other Derivative Acquisition	+560	--
2026-09-29	Theodore Samuels	Lead Independent Director	Other Derivative Acquisition	+821	--
2026-09-29	Michael McMullen	Independent director	Other Derivative Acquisition	+560	--
2026-09-08	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Open Market Disposition	-6,249	$64.57
2026-08-31	Wendy Bartie	Former Senior VP & Chief of Staff to the CEO	Derivative Exercise and Sale	-633	$66.92
2026-08-31	Wendy Bartie	Former Senior VP & Chief of Staff to the CEO	Derivative Exercise and Retained	+603	$66.92
2026-08-24	Phil Holzer	Senior Vice President	Open Market Disposition	-500	$67.50
2026-07-31	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Derivative Exercise and Sale	-26,175	$65.31
2026-07-31	Cristian Massacesi	Executive VP, Chief Medical Officer & Head of Development	Derivative Exercise and Retained	+24,997	--
2026-07-31	Cari Gallman	Executive Vice President of Corporate Affairs	Derivative Exercise and Sale	-543	$65.31
2026-07-31	Cari Gallman	Executive Vice President of Corporate Affairs	Derivative Exercise and Retained	+518	--
2026-06-29	Derica Rice	Independent Director	Other Derivative Acquisition	+672	--
2026-06-29	Phyllis Yale	Independent Director	Other Derivative Acquisition	+607	--
2026-06-29	Peter Arduini	Independent Director	Other Derivative Acquisition	+607	--
2026-06-29	Theodore Samuels	Lead Independent Director	Other Derivative Acquisition	+889	--
2026-06-29	Michael McMullen	Independent director	Other Derivative Acquisition	+607	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:11 · 仅供参考，不构成投资建议，也未考虑您的具体情况。